| 1.48 0 (0%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.81 | 1-year : | 2 |
| Resists | First : | 1.55 | Second : | 1.72 |
| Pivot price | 1.52 | |||
| Supports | First : | 1.28 | Second : | 1.07 |
| MAs | MA(5) : | 1.46 | MA(20) : | 1.5  |
| MA(100) : | 1.76  |
MA(250) : | 2.16 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 30.6 |
D(3) : | 29.3 |
| RSI | RSI(14): 47.1 | |||
| 52-week | High : | 5.65 | Low : | 1.28 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PTN ] has closed above bottom band by 34.2%. Bollinger Bands are 35.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.48 - 1.49 | 1.49 - 1.5 |
| Low: | 1.42 - 1.43 | 1.43 - 1.44 |
| Close: | 1.46 - 1.48 | 1.48 - 1.49 |
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
Mon, 09 Sep 2024
Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones - Quantisnow
Mon, 09 Sep 2024
Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones - StockTitan
Wed, 28 Aug 2024
FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED) - Quantisnow
Wed, 28 Aug 2024
FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED) - StockTitan
Fri, 21 Jun 2024
Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds - Financial Times
Mon, 20 May 2024
Palatin Technologies (PTN) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 19 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 5.6 (%) |
| Held by Institutions | 18 (%) |
| Shares Short | 1,370 (K) |
| Shares Short P.Month | 1,210 (K) |
| EPS | -2.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.1 |
| Profit Margin | 0 % |
| Operating Margin | -555.3 % |
| Return on Assets (ttm) | -110.7 % |
| Return on Equity (ttm) | -623.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.3 |
| EBITDA (p.s.) | -1.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -34 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -0.55 |
| PEG Ratio | 0 |
| Price to Book value | 14.8 |
| Price to Sales | 4.85 |
| Price to Cash Flow | -0.85 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|